Craig Hallum Begins Coverage on SOPHiA GENETICS (NASDAQ:SOPH)

Stock analysts at Craig Hallum initiated coverage on shares of SOPHiA GENETICS (NASDAQ:SOPH) in a report released on Wednesday, Marketbeat Ratings reports. The firm set a “buy” rating and a $11.00 price target on the stock. Craig Hallum’s target price indicates a potential upside of 254.84% from the company’s current price.

SOPHiA GENETICS Stock Down 8.8 %

Shares of NASDAQ SOPH opened at $3.10 on Wednesday. SOPHiA GENETICS has a 1 year low of $2.70 and a 1 year high of $7.37. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.80 and a quick ratio of 3.59. The firm has a market cap of $202.66 million, a PE ratio of -2.84 and a beta of 0.99. The company has a 50 day simple moving average of $3.43 and a 200 day simple moving average of $3.92.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its earnings results on Tuesday, November 5th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.04). The company had revenue of $15.85 million for the quarter, compared to the consensus estimate of $15.90 million. SOPHiA GENETICS had a negative return on equity of 55.06% and a negative net margin of 110.71%. During the same period in the prior year, the business earned ($0.21) earnings per share. On average, research analysts forecast that SOPHiA GENETICS will post -0.98 EPS for the current year.

Institutional Trading of SOPHiA GENETICS

Several institutional investors have recently added to or reduced their stakes in the stock. Principal Financial Group Inc. lifted its position in shares of SOPHiA GENETICS by 6.3% in the 3rd quarter. Principal Financial Group Inc. now owns 1,455,142 shares of the company’s stock worth $5,290,000 after purchasing an additional 86,764 shares during the period. Green Alpha Advisors LLC bought a new position in SOPHiA GENETICS during the third quarter worth $79,000. Federated Hermes Inc. raised its stake in SOPHiA GENETICS by 57.5% during the second quarter. Federated Hermes Inc. now owns 63,000 shares of the company’s stock worth $289,000 after buying an additional 23,000 shares during the last quarter. Finally, Banque Cantonale Vaudoise lifted its holdings in SOPHiA GENETICS by 300.0% in the second quarter. Banque Cantonale Vaudoise now owns 12,000 shares of the company’s stock valued at $55,000 after buying an additional 9,000 shares during the period. 31.59% of the stock is currently owned by institutional investors.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.